Introduction
============

Colon cancer together with lung, prostate and breast cancer constitute a threat to human health worldwide ([@b1-ol-0-0-8668]). Notably, previous findings showed that surgery had minimal adverse reaction in stage 2 patients ([@b2-ol-0-0-8668]). In addition, some treatment strategies such as adjuvant chemotherapy, were found to be effective, especially for stage 3 colon cancer ([@b3-ol-0-0-8668]). Thereby, the known critical genes in different stages of colon cancer was necessary for the diagnosis and treatment of this disease.

Various studies have been previously performed to investigate the molecular mechanism of colon cancer. For example, Yu *et al* found that methylated TBX5 may be a functional tumor suppressor gene for the diagnosis of malignancy of colon cancer ([@b4-ol-0-0-8668]). Moreover, the metachronous distant metastasis of colon cancer was ensured to be correlated with the downregulation of SASH1 (SAM- and SH3-domain containing 1) expression ([@b5-ol-0-0-8668]). Schepeler *et al* showed that the expression level of miR-320 and miR-498 was closely related to the recurrence-free survival of colon cancer ([@b6-ol-0-0-8668]). miR-21 was also confirmed to be upregulated in stage 2 colon cancer by participating in the immune process ([@b7-ol-0-0-8668]). In addition, transforming growth factor β1 could prevent an organized hyperplasia in the early transition, and further suppress colon cancer ([@b8-ol-0-0-8668]). Although these genes, miRNAs and pathways were identified, differentially expressed genes (DEGs) in different staging and their potential mechanism remain to be determined.

In order to investigate more colon cancer-related genes in different stages, DEGs in four stages compared with controls were identified in this study, and series test of clusters were processed. In addition, functional and pathway enrichment analysis was used for these DEGs. Finally, various networks including a pathway relation network, gene signal network and gene co-expression network were constructed.

Materials and methods
=====================

### Microarray data

The gene expression profile E-GEOD-62932 was extracted from the ArrayExpress Archive, including 64 colon cancer tissues and 4 healthy control samples ([@b9-ol-0-0-8668]). The 64 colon cancer tissues included 12 samples in stage 1, 17 in stage 2, 20 in stage 3, and 15 in stage 4. Platform information of this profile was GPL570 \[HG-U133_Plus_2\] Affymetrix Human Genome U133 Plus 2.0 Array.

### Data preprocessing and DEGs screening

The obtained probe sets were converted into expression value matrix and background correction, normalization and summarizing were performed using the Robust Multi-chip Average algorithm. Based on the information of Affymetrix (\*.transcript.csv), the probe sets were annotated. The annotated data were screened with the threshold of \>0.8 median (normalized unscaled standard errors) \<1.2 and \>0.25 median (relative log expression) \<0.25.

DEGs between colon cancer in various stages and normal tissues were identified by significance analysis of microarrays method with the cut-off criteria of P\<0.05 ([@b10-ol-0-0-8668]).

### Series test of clusters

The gene expression profiles were always changed with tumor development. In the present study, series test of cluster (STC) analysis was used to obtain the significant trending models related to tumor stage and their involved DEGs ([@b11-ol-0-0-8668]). Clusters with P\<0.05 were regarded as statistically significant.

### Functional and pathway enrichment analysis

Gene Ontology (GO) is a cross-species and comprehensive database, which was constructed by the GO Consortium ([@b12-ol-0-0-8668]). Similarly, the Kyoto Encyclopedia of Genes and Genomes (KEGG) is a powerful tool for analysis of biological metabolism and metabolic network ([@b13-ol-0-0-8668]). Based on the abovementioned databases, GO functional and KEGG pathway enrichment analysis were processed for identified DEGs with the threshold of P\<0.05. The Fisher\'s exact test and multiple comparisons were used to calculate the significance of GO terms and pathways, and false discovery rate (FDR) was the adjusted P-value.

### Construction of pathway relation network

The pathway relation network was constructed based on information from the KEGG database. From this network, a signal transduction relationship was obtained. In addition, upstream regulatory pathways and downstream effective pathways were identified.

### Gene signal and gene co-expression network construction for common DEGs

DEGs in GO terms and KEGG pathways were inserted based on the same symbol. The obtained DEGs were regarded as common DEGs. Gene signal information was collected from the KEGG database. The common DEGs were mapped into the whole network and the gene signal network of common DEGs in colon cancer was generated. Additionally, the gene co-expression network was a weighted network that was constructed based on gene expression value and their correlation indexes. The two networks were visualized by Cytoscape ([@b14-ol-0-0-8668]).

Results
=======

### DEG screening and series test of cluster

Based on the threshold of DEGs, 1,543 DEGs were screened to be associated with colon tumor development compared with control samples. Then, the DEGs with the same trend were clustered. A total of 16 clusters with statistical significance were obtained, including profile 14, 67, 5 and 2 ([Fig. 1](#f1-ol-0-0-8668){ref-type="fig"}).

### Functional and KEGG pathway enrichment

The screened DEGs were enriched into various GO terms, such as small molecule metabolic process (FDR=1.57E-36), cell division (FDR=1.00E-29) and mitotic cell cycle (FDR=9.07E-28) ([Table I](#tI-ol-0-0-8668){ref-type="table"}). In addition, the DEGs were gathered into different pathways including metabolic pathways (FDR=1.57E-21), cell cycle (FDR=8.23E-12) and progesterone-mediated oocyte maturation (FDR=3.56E-09) ([Table II](#tII-ol-0-0-8668){ref-type="table"}).

### Construction of the pathway relation network

The pathway relation network was constructed with 57 nodes and 158 edges. The hub nodes were glycolysis/gluconeogenesis (Degree=17), apoptosis (Degree=17), citrate cycle (TCA cycle) (Degree=16) and pathways in cancer (Degree=13). Notably, pathways in cancer (Outdegree=13), phenylalanine metabolism (Outdegree=4) and gap junction (Outdegree=4) were upstream pathways, while cytokine-cytokine receptor interaction (Indegree=5) and oxidative phosphorylation (Indegree=4) were downstream pathways ([Fig. 2](#f2-ol-0-0-8668){ref-type="fig"}).

### Gene signal network and gene co-expression network construction for common DEGs

Based on the same gene symbol, a total of 328 common DEGs were obtained, such as adenosylhomocysteinase-like 2, oxytocin receptor, aquaporin 8 and hedgehog interacting protein. As shown in [Fig. 3](#f3-ol-0-0-8668){ref-type="fig"}, the gene signal network was constructed with 71 nodes and 146 edges. The hub nodes were adenylate cyclase 9 (Degree=18), ectonucleoside triphosphate diphosphohydrolase 5 (Degree=18) and protein kinase, cAMP-dependent, catalytic, β (Degree=14).

The gene co-expression network was constructed with 161 nodes and 211 edges ([Fig. 4](#f4-ol-0-0-8668){ref-type="fig"}). In this network, the hub nodes with a higher degree were ATP-binding cassette, sub-family D, member 3 (ABCD3, Degree=19), carnitine palmitoyltransferase 2 (CPT2, Degree=17) and amylo-α-1, 6-glucosidase, 4-α-glucanotransferase (AGL, Degree=15). Moreover, this network showed that ABCD3 has a positive relationship with various DEGs, including ankyrin 3, adenylate cyclase 9 and acyl-coA dehydrogenase, and short/branched chain.

Discussion
==========

Over 75% of colon cancer occurs in individuals with little or no genetic risk ([@b15-ol-0-0-8668]). However, various gene expressions and their related functions and pathways were altered with the increasing of grade of the tumor. These genes provided the biomarkers for colon cancer of each stage and also suggest effective treatment targets. In the present study, several significant DEGs were screened and resulted in participation in the pathogenesis of colon cancer, including ABCD3, CPT2, AGL and (Junctional adhesion molecule B) JAM2.

ABCD3 encoded a protein of a member of ATP-binding cassette (ABC) transporters, which is involved in peroxisomal import of fatty acids or fatty acyl-CoAs in the organelle ([@b16-ol-0-0-8668]). Previous findings showed by targeting the expression of the multidrug resistance (MDR)-related ABC transporters, that reversal of MDR could be realized and MDR in cancer could be solved ([@b17-ol-0-0-8668]). Various ABC transporters such as Ped3p, were confirmed to provide substrates for fatty acid β-oxidation ([@b18-ol-0-0-8668]). In addition, there was evidence that colorectal cancer cells could be induced to apoptosis by the inhibition of fatty acid oxidation ([@b19-ol-0-0-8668],[@b20-ol-0-0-8668]). Similar to the results in this study, ABCD3 was found to participate in ABC transporters, transmembrane transport, fatty acid β-oxidation and ATP catabolic process. In addition, the results in this study have shown that ABCD3 belonged to profile 5 in series test of cluster. The expression of this gene was significantly decreased in stage 1 and 2 of colon cancer samples. Thus, we inferred that ABCD3 may be used as a biomarker for the early detection of colon cancer.

Moreover, CPT2 was a key DEG in profile 5, which was involved in small molecule metabolic process, cellular lipid metabolic process, carnitine shuttle, fatty acid degradation and peroxisome proliferator-activated receptor (PPAR) signaling pathway in the present study. As known, this gene mainly existed in mitochondrion and nucleus and was closely associated with mitochondrial long-chain fatty-acid oxidation disorders ([@b21-ol-0-0-8668]). In tumor-bearing rat models, Seelaender *et al* found that the expression of mitochondrial inner-membrane CPT2 was markedly decreased ([@b22-ol-0-0-8668]). Additionally, previous bioinformatic findings showed that the pathway of fatty acid metabolism involved various altered expressed genes and was confirmed to have a close link with colorectal carcinogenesis ([@b23-ol-0-0-8668]). Furthermore, Wang and Dubois found that the PPAR signaling pathway could promote the emergence of chronic colonic inflammation and colitis-related tumors ([@b24-ol-0-0-8668]). Of note, the results in the present study showed that the PPAR signaling pathway was the upstream pathway of fatty acid degradation. The abovementioned information shows that CPT2 is a potentially critical biomarker for colon cancer by participating in the fatty acid metabolic process and PPAR signaling pathway.

Another critical DEG, AGL was found to have a positive relationship with CPT2 in the present study. AGL encodes the glycogen debrancher enzyme, which is involved in glycogen degradation ([@b25-ol-0-0-8668]). In bladder tumor, AGL was confirmed to participate in the induction of hyaluronic acid synthesis and further regulate tumor growth ([@b26-ol-0-0-8668]). To the best of our knowledge, there is currently no correlative literature showing the relevance between AGL and colon. However, AGL was significantly altered and involved in the carbohydrate metabolic process, response to glucocorticoid stimulus and glucose metabolic process. In 1984, Holroyde *et al* showed that diverse abnormalities of the carbohydrate metabolic process often occurred in cancer cachexia, such as colorectal cancer ([@b27-ol-0-0-8668]). In addition, aerobic glycolysis was ensured to be a metabolic adaptation that promotes the proliferation of colorectal cancer cells ([@b28-ol-0-0-8668]). Based on the abovementioned information, we hypothesized that AGL was a potential biomarker for the diagnosis of colon cancer.

JAM2 encodes a type I membrane protein that functions as an adhesive ligand for interacting with the number of immune cell types ([@b29-ol-0-0-8668]). The findings of a previous study revealed that JAM2 played an important role in motility and its adhesion process of colon cancer cells ([@b30-ol-0-0-8668]). In addition, Royse *et al* found that JAM2 altered the expression in early- and late-stage colon tumors, and is also closely associated with PTEN, which is a tumor suppressor ([@b31-ol-0-0-8668]). In the present study, JAM2 was gathered into tight junction, cell adhesion molecules and in blood coagulation. Consistent with previous studies, the indexes of blood coagulation were closely associated with the progression of colon cancer ([@b32-ol-0-0-8668]). Moreover, various blood coagulation inhibitors were found to be beneficial for colon cancer patients ([@b33-ol-0-0-8668]). Thus, JAM2 may be involved in the pathogenesis of colon cancer by participating in cell adhesion molecules and blood coagulation.

In summary, the identified DEGs including ABCD3, CPT2, AGL and JAM2 constitute potential biomarkers for the diagnosis of colon cancer by participating in various functions and pathways. The validation of these biomarkers identified is to be conducted in future studies.
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###### 

Top 5 GO terms of differentially expressed genes.

  GO ID        GO Name                            Diff gene counts in GO   Enrichment Score   P-value    FDR
  ------------ ---------------------------------- ------------------------ ------------------ ---------- ----------
  GO:0044281   Small molecule metabolic process   129                      3.905874858        5.67E-40   1.57E-36
  GO:0051301   Cell division                      56                       7.834124719        7.24E-33   1.00E-29
  GO:0000278   Mitotic cell cycle                 59                       6.707641713        9.84E-31   9.07E-28
  GO:0000236   Mitotic prometaphase               28                       11.55533396        7.75E-22   5.36E-19
  GO:0000087   M phase of mitotic cell cycle      35                       7.295034066        7.28E-20   4.02E-17

GO, Gene Ontology; FDR, false discovery rate.

###### 

The top 5 pathways of differently expressed genes.

  Pathway ID   Pathway name                              Diff gene counts in pathway   Enrichment score   P-value    FDR
  ------------ ----------------------------------------- ----------------------------- ------------------ ---------- ----------
  1,100        Metabolic pathways                        95                            3.297358904        6.37E-24   1.57E-21
  4,110        Cell cycle                                23                            7.654743119        6.66E-14   8.23E-12
  4,914        Progesterone-mediated oocyte maturation   17                            8.157835437        5.00E-11   3.56E-09
  4,114        Oocyte meiosis                            19                            7.00099953         5.76E-11   3.56E-09
  5,200        Pathways in cancer                        29                            3.659946318        5.29E-09   2.61E-07

FDR, false discovery rate.
